Mesoporous mHAP as Carrier of Etoposide for Lung Cancer Chemotherapy and Hyperthermia

• Main Authors: Po-An Shih, 施柏安
• Other Authors: Feng-Huei Lin
• Format: Others
• Language: zh-TW
• Published: 2013
• Online Access: http://ndltd.ncl.edu.tw/handle/22384709965289304851

碩士 === 國立臺灣大學 === 醫學工程學研究所 === 101 === Cancer is the fatal disease in the world. Clinical cancer treatment can be commonly classified into three categories: surgery, radiation therapy and chemotherapy. With research gradually developing, there is an emerging treatment, hyperthermia, which can reduce the side effect of cancer treatment. Hyperthermia can lead cancer cell to death by rising the temperature between 42-47°C in the body tissue. Our topic focuses on the combination of hyperthermia and chemotherapy in order to enhance the efficiency of cancer treatments. As a medicine carrier, magnetic hydroxyapatite (mHAP) shows good biocompatibility. By adding egg white in co-precipitation method to form hydroxyapatite (Ca10(PO4)6(OH)2) and then calcinating it at 800°C to remove carbon, we can develop mesoporous hydroxyapatite. After iron ion (Fe2+) substituting the calcium ion (Ca2+) of hydroxyapatite, we develop mesoporous magnetic hydroxyapatite. It has specific absorption rate at about 182 W/g and it can rise to hyperthermia temperature within ten minutes by adding alternating magnetic field. Besides, it also has superparamagnetic property according to SQUID analysis. Since we use anticancer drug Etoposide is hydrophobic, we use stearic acid to change hydrophilic mesoporous magnetic hydroxyapatite into hydrophobic one. Therefore, we can load Etoposide on mesoporous magnetic hydroxyapatite by adsorption. The loading efficiency is 26.12% by UV/Vis analysis. Mesoporous magnetic hydroxyapatite shows good biocompatibility in 3T3 cell by WST-1 assay. After keeping hyperthermia temperature (42-43°C) for 20 minutes, the cell viability of A549 cells is reduced by 40%. Etoposide release causes cytotoxicity and kills more cancer cells after three days. Evidence shows that combination of hyperthermia and chemotherapy can enhance cancer treatment of hyperthermia or chemotherapy and cause about 80% of cytotoxicity of A549 lung cancer cells after three day treatment. Combination of hyperthermia and chemotherapy can enhance cancer treatment additively and fulfill therapy in dual function.